Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Disease Areas › Cancer › FDA Approves First-Line Opdivo, Yervoy Plus Chemo for Patients with NSCLC Regardless of PD-L1 Status

FDA Approves First-Line Opdivo, Yervoy Plus Chemo for Patients with NSCLC Regardless of PD-L1 Status

May 27, 2020
|
staff reporter

NEW YORK – Bristol Myers Squibb (BMS) yesterday announced that the US Food and Drug Administration (FDA) has approved the combination of the immune checkpoint inhibitor drugs nivolumab (Opdivo) and ipilimumab (Yervoy) together with two cycles of platinum-doublet chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer. The treatment combination was approved for patients without EGFR or ALK gene mutations regardless of their PD-L1 status.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
22
Featured Webinar

Trends in Variant Interpretation Workflows: Expert Insights to Advance NGS Oncology Profiling

Sponsored by
Qiagen

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

What's Popular?

In Cancer

  1. Researchers ID Four Small Cell Lung Cancer Subtypes, Suggest Future Treatment Implications

    Premium

  2. Tempus, Bristol Myers Squibb Expand Cancer Biomarker Alliance

  3. Merck Nabs EU Keytruda Approval for MSI-High, Mismatch Repair Deficient Colorectal Cancer

  4. Cardiff Oncology to Begin Phase II Onvansertib Trial in Pancreatic Cancer

  5. Small Cell Lung Cancer Study Uncovers Disease-Associated Germline Mutations

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.